Mission in a Minute

Proteomics: March highlight


For decades, Thermo Fisher Scientific’s technologies have transformed how scientists study human biology. Just as we enabled the Human Genome Project to drive understanding of how genes regulate disease, our latest platforms are being leveraged to study proteins, the primary molecules controlling human health, through a field of research known as proteomics.

Building on our legacy of innovation, our Thermo Scientific Orbitrap Astral Mass Spectrometer is helping to push the boundaries of proteomic research. Designed to enable deeper analysis of the human proteome, this cutting-edge instrument is empowering scientists around the world to rethink what’s possible for the future of precision medicine.

Further demonstrating our role in transformative research, the UK Biobank Pharma Proteomics Project recently selected our Olink Explore HT for the world’s largest proteomics study. Early research showed the potential of these findings to improve the accuracy and potential for early cancer diagnoses, identifying early protein risk factors for certain cancers up to seven years prior to formal diagnosis.


 This data will help validate and identify new drug targets, advance diagnostics and help accelerate targeted drug discovery.

 

Ensuring a deeper understanding of disease signals unlocks new avenues in therapeutic development. By advancing proteomics research and discovery, Thermo Fisher’s technologies are playing an essential role in enabling improved patient outcomes.